Antidiabetic medications and polypharmacy

Clinics in Geriatric Medicine

Volumn 31, Issue 1, 2015, Pages 17-27

  Peron, Emily P ^a   Ogbonna, Kelechi C ^a   Donohoe, Krista L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Adverse drug events; Diabetic complications; Geriatric syndromes; Hypoglycemic agents; Polypharmacy

Indexed keywords

ACARBOSE; ALOGLIPTIN; ANTIDIABETIC AGENT; BROMOCRIPTINE MESILATE; CANAGLIFLOZIN; CHLORPROPAMIDE; COLESEVELAM; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN; LINAGLIPTIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; ROSIGLITAZONE; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; UNINDEXED DRUG;

AGING; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FALL RISK; FRACTURE; GERIATRIC CARE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIFE EXPECTANCY; MEDICATION COMPLIANCE; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PATIENT CARE; POLYPHARMACY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; URINE INCONTINENCE; WEIGHT GAIN; WEIGHT REDUCTION; AGE; AGED; COMPLICATION; DIABETES MELLITUS, TYPE 2; RISK FACTOR;

AGE FACTORS; AGED; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; POLYPHARMACY; RISK FACTORS;

EID: 84912572944     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2014.08.017     Document Type: Review

References (45)

1. Slone Epidemiology Center. Patterns of medication use in the United States. Available at: . 2006. Accessed January 25, 2014. http://www.bu.edu/slone/files/2012/11/SloneSurveyReport2006.pdf.
2. American Diabetes Association Standards of medical care in diabetes - 2014. Diabetes Care 2014, 37(Suppl.1):S14-S80. 10.2337/dc14-S014.
3. Boyd C.M., Darer J., Boult C., et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005, 294(6):716-724. 10.1001/jama.294.6.716.
4. Murray M.D., Darnell J., Weinberger M., et al. Factors contributing to medication noncompliance in elderly public housing tenants. Drug Intell Clin Pharm 1986, 20(2):146-152.
5. Ferner R.E., Aronson J.K. Communicating information about drug safety. BMJ 2006, 333(7559):143-145. 10.1136/bmj.333.7559.143.
6. Field T.S., Gurwitz J.H., Avorn J., et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001, 161(31):1629-1634. 10.1001/archinte.161.13.1629.
7. Kirkman M.S., Briscoe V.J., Clark N., et al. Diabetes in older adults: a consensus report. JAm Geriatr Soc 2012, 60(12):2342-2356. 10.1111/jgs.12035.
8. Rochon P.A., Gurwitz J.H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997, 314(7115):1096-1099. 10.1136/bmj.315.7115.1096.
9. Keller R.B., Slattum P.W. Strategies for prevention of medication-related falls in the elderly. Consult Pharm 2003, 18(3):248-258.
10. Yau R.K., Strotmeyer E.S., Resnick H.E., et al. Diabetes and risk of hospitalized injury among older adults. Diabetes Care 2013, 36(12):3985-3991. 10.2337/dc13-0429.
11. Zammitt N.N., Frier B.M. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005, 28(12):2948-2961. 10.2337/diacare.28.12.2948.
12. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. JAm Geriatr Soc 2012, 60(4):616-631. 10.1111/j.1532-5415.2012.03923.x.
13. Berlie H.D., Garwood C.L. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother 2010, 44(4):712-717. 10.1345/aph.1M551.
14. The American Geriatrics Society. 2010 AGS/BGS clinical practice guideline: prevention of falls in older persons. Available at: . Accessed January 5, 2013. http://www.american-geriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_%20recommendations/2010/.
15. Solomon D.H., Cadarette S.M., Choudhry N.K., et al. Acohort study of thiazolidinediones and fractures in older adults with diabetes. JClin Endocrinol Metab 2009, 94(8):2792-2798. 10.1210/jc.2008-2157.
16. Zeina H.A., Havstad S.L., Wells K., et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. JClin Endocrinol Metab 2010, 95(2):592-600. 10.1210/jc.2009-1385.
17. Wedick N.M., Barrett-Connor E., Knoke J.D., et al. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: the Rancho Bernardo study. JAm Geriatr Soc 2002, 50(11):1810-1815.
18. Fowler M.J. Diabetes treatment, part 2: oral agents for glycemic management. Clin Diabetes 2007, 25(4):131-134. 10.2337/diaclin.25.4.131.
19. Hermansen K., Mortensen L.S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007, 30(12):1127-1142. 10.2165/00002018-200730120-00005.
20. Moore E.M., Mander A.G., Ames D., et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 2013, 36(10):2981-2987. 10.2337/dc13-0229.
21. Singh S., Loke Y.K., Furberg C.D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007, 30(8):2148-2153. 10.2337/dc07-0141.
22. U.S. Food and Drug Administration. Information for healthcare professionals: Pioglitazone HCl (marketed as Actos, Actoplus Met, and Duetact). Published August 2007. Updated August 14, 2013. Available at: . Accessed January 5, 2014. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124178.htm.
23. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. Published November 29, 2013. Updated January 9, 2014. Available at: . Accessed February 15, 2014. http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm.
24. Invokana (canagliflozin) [package insert] 2013, Janssen Pharmaceuticals, Inc, Titusville (NJ).
25. Boyd C.M., McNabney M.K., Brandt N., et al. Guiding principles for the care of older adults with multimorbidity: an approach for clinicians. JAm Geriatr Soc 2012, 60(10):E1-E25. 10.1111/j.1532-5415.2012.04188.x.
26. Tinetti M.E., Bogardus S.T., Agostini J.V. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. NEngl J Med 2004, 351(27):2870-2874. 10.1056/NEJMsb042458.
27. Brown A.F., Mangione C.M., Saliba D., et al. Guidelines for improving the care of the older person with diabetes mellitus. JAm Geriatr Soc 2003, 51(5 Suppl Guidelines):S265-S280. 10.1046/j.1532-5415.51.5s.1.x.
28. Sinclair A.J., Paolisso G., Castro M., et al. European Diabetes Working Party for older people 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab 2011, 37(Suppl. 3):S27-S38. 10.1016/S1262-3636(11)70962-4.
29. Wallace J.I. Management of diabetes in the elderly. Clin Diabetes 1999, 17(1):19-25. Available at:, Accessed February 15, 2014. http://journal.diabetes.org/clinicaldiabetes/v17n11999/Pg19.htm.
30. Yourman L.C., Lee S.J., Schonberg M.A., et al. Prognostic indices for older adults: a systematic review. JAMA 2012, 307(2):182-192. 10.1001/jama.2011.1966.
31. Lee S.J., Lindquist K., Segal M.R., et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006, 295(7):801-808. 10.1001/jama.295.7.801.
32. Schonberg M.A., Davis R.B., McCarthy E.P., et al. Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey. JGen Intern Med 2009, 24(10):1115-1122. 10.1007/s11606-009-1073-y.
33. Wells B.J., Jain A., Arrigain S., et al. Predicting 6-year mortality risk in patients with type 2 diabetes. Diabetes Care 2008, 31(12):2301-2306. 10.2337/dc08-1047.
34. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352(9139):854-865. 10.1016/S0140-6736(98)07037-8.
35. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9178):837-853. 10.1016/S0140-6736(98)07019-6.
36. Vijan S., Hofer T.P., Hayward R.A. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997, 127(9):788-795. 10.7326/0003-4819-127-9-199711010-00003.
37. National Diabetes Education Program. The Facts about diabetes: a leading cause of death in the U.S. National Diabetes Education Program. 2007. Available at: . Accessed February 15, 2014. http://ndep.nih.gov/diabetes-facts/.
38. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. NEngl J Med 2008, 358(24):2545-2559. 10.1056/NEJMoa080274.
39. Miller M.E., Bonds D.E., Gerstein H.C., et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010, 340:b5444. 10.1136/bmj.b5444.
40. Duckworth W.C., Abraira C., Moritz T.E., et al. Glucose control and vascular complications in veterans with type 2 diabetes. NEngl J Med 2009, 360(2):129-139. 10.1056/NEJMoa0808431.
41. Duckworth W.C., Abraira C., Moritz T.E., et al. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA diabetes trial. JDiabetes Complications 2011, 25(6):355-361. 10.1016/j.jdiacomp.2011.10.003.
42. ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEngl J Med 2008, 358(24):2560-2572. 10.1056/NEJMoa0802987.
43. Committee on Quality of Health Care in America: Institute of Medicine Crossing the quality chasm: a new health system for the 21st century 2001, The National Academies Press, Washington, DC.
44. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379. 10.2337/dc12-0413.
45. Durso S. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA 2006, 295(16):1935-1940. 10.1001/jama.295.16.1935.